Vivos Therapeutics Stock Climbs 9% On Positive Pediatric Sleep Apnea Study

(RTTNews) - Vivos Therapeutics, Inc. (VVOS) rose 8.83 percent to $3.30 on Thursday after the European Journal of Pediatrics published favorable results from a multicenter clinical trial supporting the company's patented Daytime-Nighttime Appliance for treating obstructive sleep apnea in children.

The stock opened at $3.54 and traded between $3.26 and $3.89 on volume of 1.29 million shares, significantly above its average of 125,000 on the Nasdaq. The move brought the stock closer to its 52-week high of $6.28, up from a previous close of $3.04. Its 52-week low stands at $1.97.

The study highlighted that 79 percent of participants showed improvement, with 17 percent seeing complete resolution of symptoms and no safety concerns reported.